MTF stands behind amnion products; will fight patent infringement charge

EDISON, N.J., April 28, 2014 /PRNewswire/ -- The Musculoskeletal Transplant Foundation (MTF) has been notified that on April 21, 2014, MiMedx Group, Inc. (MiMedx) filed a complaint in the United States District Court for the Northern District of Georgia, naming MTF, together with Liventa Bioscience, Inc. and Medline Industries Inc., as defendants.  The complaint alleges patent infringement by MTF of four MiMedx patents.  MTF does not believe it infringes any of the patents and is prepared to defend itself, which includes taking such appropriate counter-measures against MiMedx as are necessary and warranted to protect its amnion products and customers.  MTF intends to vigorously defend its rights and ensure that MiMedx does not unlawfully interfere with any of its business partners or markets.  MTF has the resources and stamina to take the two, three or even four years that may be needed to prove its position in the courts.

Amnion has been used for opthalmic and burn applications for decades and the fundamental processing technology is well known.  The MTF subsidiary in Germany, DIZG, has processed and distributed amnion for twenty years. While minor features and modest improvements can be protected by patents, amnion is and has been processed by many tissue banks for many years.

About MTF:

The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987, MTF has received tissue from more than 100,000 donors and distributed more than 5 million grafts for transplantation. For more information, visit www.mtf.org

Contact: Cindy Gordon, Issues Management/Insight Communication
609/252-1300

SOURCE The Musculoskeletal Transplant Foundation